Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Ophthalmology Dermatology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Pancreatic diseases

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for pancreatic diseases

9 trials tracked for pancreatic diseases: 5 in phase 3 or 4 and 3 with published results. The most-cited published study has 135 citations.

9Trials tracked

5Phase 3 & 4

0Recruiting

3With published results

Phase distribution

Phase 4 2 Phase 3 3 Phase 2 1 Other / NA 3

Phase 3 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Completed · 135 cited
Phase 3 Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy? Completed · 127 cited
Phase 4 IV Acetaminophen for Post-Operative Pain Management in Enhanced Recovery After Surgery (ERAS) Population Completed · 11 cited
Phase 4 Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy Completed
Phase 3 Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP) Completed
Phase 2 A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer Completed

Show 3 more trials

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Pancreatic diseases: what the trials found

Clinical evidence for pancreatic disease management includes the use of Acetaminophen Injectable Product ¹. Additionally, Drotaverine hydrochloride has been evaluated in Phase 3 trials ⁵, and Cefoxitin was assessed in a Phase 3 study ⁴.

Nab-paclitaxel has been investigated across multiple phases; in one Phase 3 trial, the number of participants with Grade 3-4 clinical chemistry laboratory-detected abnormalities was reported as 7, 3, 9, 3, 9, and 2 ³, while a Phase 2 study also utilized Nab-paclitaxel ⁶.

Monitoring technology, specifically the Vigileo Monitor, has been established in Phase 4 trials for this condition ².

Recent results — preliminary, needs further review

Lipacreon showed results in nutritional endpoints including BMI (ranging from 20.193 to 20.720), Serum Total Protein (6.579 to 6.955), and Albumin (3.688 to 3.984), but these findings are not yet corroborated ⁷.
Pancrelipase was evaluated for nutritional endpoints including BMI, Serum Total Protein, and Albumin, though results remain unconfirmed ⁸.
The Bihormonal Bionic Pancreas was studied in a small cohort (N=10) but remains unconfirmed ⁹.

For the clinician treating this condition

Nab-paclitaxel is utilized in both Phase 2 and Phase 3 settings for pancreatic conditions, with specific data available regarding laboratory-detected abnormalities [3, 6].
Pharmacological interventions include Acetaminophen Injectable Product ¹, Drotaverine hydrochloride ⁵, and Cefoxitin ⁴.
The Vigileo Monitor is an established tool for monitoring in this patient population ².

AI synthesis of 9 cited trials, updated Jun 27, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.